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Myocardial infarction (MI) or heart attack occurs when the bloodstream to the heart is 
blocked, which may destroy a part of the heart muscle (or myocardium) and form perdurable 
scarred tissue. The infarcted myocardial muscle nowadays has no revival treatments, and also 
transplantation is limited as an option. Tissue engineering has the potential to restore myocardial 
function after an MI by fabricating tailored tissues for treatment. For tissue engineering, three-
dimensional (3D) bioprinting is a fabrication method to create 3D constructs with living cells, 
which would be impossible by other traditional methods. Although various biomaterials, 
biologically-derived or synthetic, are available, only a few can be used in 3D bioprinting of 
cardiovascular tissues due to their mechanical weakness of natural biomaterials and/or limited 
bioactivity (in terms of promoting cell functions) of synthetic ones. The present study aims to 
develop a novel biomaterial solution for bioprinting (referred to as bioink) and on this basis, to 
bioprint cell-laden patches and characterize the patches in vitro for potential use in MI treatment. 
 For this,  a new bioink was formulated based on chicken egg white (EW) and sodium 
alginate (Alg). EW, as a rich source of albumin and well-known for its drug delivery applications, 
has been strategically combined with Alg, a common printable polysaccharide with a non-
thrombogenic nature. EW was utilized to improve bioactivity and cell adhesion sites and sodium 
alginate was considered as an extrudability enhancer to provide good printability. The following 
research objectives were pursued: I) develop and rheologically characterize the albumin-based 
bioink by adding minimal amounts of alginate as a printability enhancer biomaterial; II) 
characterize the mechanical properties of the 3D printed albumin-based patches by compression 
testing and monitoring the swelling and degradation behavior; and III) characterize the biological 
properties of the 3D bioprinted cell-laden albumin-based patch by examining the in vitro cell 
viability.  
EW-Alg blends with different alginate concentrations were synthesized by mixing the 
pasteurized egg white with sodium alginate powder. Then the blends were tested in terms of their 
rheological behavior and showed a non-Newtonian shear-thinning functioning, i.e. the increase of 
shear strain led to a decline in viscosity. Moreover, the addition of each 0.5 gram alginate in 100 




and handling. Hence, the more alginate was used in the solution, the higher the blend's viscosity 
and the required extrusion pressure. 
Compression elastic moduli of the 3D printed patches from the printable EW-Alg blends 
(2.0, 2.5, and 3.0% Alg in EW) with the range 20-27 kPa showed the similarity of these constructs 
mostly to human cadaver limb specimens with 10-38 kPa compressive elastic modulus. 
Furthermore, swelling measurements performed in phosphate-buffered saline (PBS) showed 
swelling ratios of more than 1800% for all three concentrations of the EW-Alg blend, representing 
these 3D printed patches' ability to uptaking ionic fluids from a body-like environment. Also, all 
of the constructs showed signs of biodegradation within a month.  
The EW-2.0%Alg blend, which had the highest egg white ratio to alginate and the lowest 
viscosity, was 3D bioprinted as a cell-laden bioink. The loaded human umbilical vein endothelial 
cells (HUVECs) survival rate was more than 90% in all of the time points within a week, showing 
high biocompatibility of the EW-Alg bioink. 
The present study developed an egg white-based bioink for 3D cardiac patch bioprinting. 
Fabricated patches exhibited suitable mechanical properties and biocompatibility in vitro, to be 
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Chapter 1: Introduction 
 
1.1 Myocardial Infarction 
Heart attack or myocardial infarction (MI) occurs when one or multiple heart coronary 
arteries are disabled to deliver the blood to the heart, causing irreversible damage to the heart 
muscle [1]. In contrast with other organs, heart muscle regeneration is almost absent in adulthood 
since the cardiomyocyte differentiation is almost terminated [2]. 
A variety of cardiovascular diseases and disorders can lead to MI ( such as the formation 
of blood clots, coronary diseases, and neurological disorders), and MI continues to be a deadly 
problem globally each year [3]. Current solutions include different surgeries to remove the 
obstruction that had led to the occurred infarction or compensating for the infarcted myocardium's 
function. Coronary bypass surgery, angioplasty, stenting, implanting pacemakers or defibrillators, 
and valve replacement are some of the conventional proceedings [4]. Also, in the acute cases where 
the infarcted area is large and heart failure is in the end-stage, heart transplantation is needed. 
However, the number of donations has never been enough, and also the risk of the rejection of the 
donor's heart exists. 
1.2 Cardiac Tissue Engineering 
Lack of curing methods that can reverse the scarred heart muscle and restore its function 
have increased the tissue engineering research demands to develop new treatments with 
regenerative capacity.  
The first 3D cardiac structure was constructed by Moscona et al. in 1952 [5]. In 1959, this 
group generated spheroid aggregates from embryonic chicken heart cells. They cultivated freshly 
isolated cells in Erlenmeyer flasks under continuous gyration [6]. Since then, different heart tissue 
engineering approaches such as cell transplantation, injectable scaffolds, and myocardial patches 
have been developed to help repair the damaged site [7]. The purpose is engineering the infarcted 
region for healing and restoration of its innate function. 
In the cell transplantation method, a suspension of cells that usually contains stem cells or 




the cardiac cells within the scarred region [8]. The main challenge here is the transplanted cells' 
low survival rate due to various reasons such as inflammation, fibrosis, and/or shortage of blood 
supply [9]. The lack of extracellular matrix (ECM) support in this method plays a critical role in 
cell fate and survival due to the deprivation of environmental signaling and transportation, which 
are normally provided by ECM [10]. 
Injectable hydrogels may be an approach to solicit ECM support. This approach is an in-
situ reconstruction of the tissue. Injectable structures, usually made of water-soluble biomaterials, 
are combined with necessary biological factors for regeneration, such as growth factors or cells 
(like stem cells), and directly are injected into the infarcted area of the heart [11][12]. This method, 
although less invasive than implanting in vitro engineered tissues, has some disadvantages. The 
presence of the crosslinking agents inside the body and unreacted particles creates a risk of further 
toxicity problems [13]. Also, the size, shape, and development of the engineered construct are not 
entirely controllable. Besides, similar to the cell transplantation approach, the cell survival rate is 
low because of the surgical stress cells incur during the injection process [7]. 
In vitro made cardiac patches are the other tissue engineering approach in which an 
implantable construct (or patch) provides physical and biochemical cues for myocardium 
regeneration. These engineered patches can be generally classified into two main groups called 2D 
cell sheets and 3D cell-laden patches [14]. In the cell sheet method, myocardial cells are cultured 
in a dish and are connected by cell junctions. Usually, the culture dish button is covered by a 
temperature-sensitive polymer such as poly N-isopropyl acrylamide (PIPAAm) to facilitate 
detaching the cell sheet from the plate by changing the temperature [15]. Single-layer sheets can 
then be assembled on top of each other to make 3D cardiac constructs. This layered structure 
arranges well-aligned cells that are required for the proper pulsation feature in cardiac tissue. This 
approach has some challenges as the number of layers of the construct increases. For example, 
weak electrical and morphological communications, plus inadequate perfusion of growth factors 
and biological agents among the layers, are common problems in this method due to lack of a 





An alternative approach is 3D porous interconnected patches in which cells are suspended 
in a matrix of biomaterial. This design gives us more freedom to gather desirable features, such as 
employing a combination of fabrication methods, cell types, and biomaterials. 3D printing and 
electrospinning are two conventional methods for the fabrication of 3D architectures. These 
methods enable tailoring patch properties via optimization of the materials and processing 
parameters [16]. This control can have subsequent roles in the manipulation of cell behavior for 
tissue engineering [16]. 
Electrospun constructs often have random architectures, whereas, in 3D printing, 3D 
models are built in a computer-controlled layer-by-layer process. Such an organized design 
empowers the integration of more complicated features like vasculature networks owing to having 
control over the patch’s architecture [17][18]. In 3D printing, cells can be incorporated into 
biomaterials and pattern thick tissue living constructs that could not be formed using other 
fabrication methods [19]. Using this method can result in porous constructs (or matrices) with 
specific shapes and dimensions that subsequently might affect initial adhesion, proliferation, and 
differentiation of the cultured cells in the presence of corresponding bioactive components such as 
growth factors and enzymes [20]. This technology gives us the hope of fabricating patches with 
similar morphology and accuracy to the native ECM [21]. 




1.3 Extrusion-Based 3D Printing  
Extrusion-based 3D printing is an additive manufacturing methodology in which materials 
are selectively dispensed through a nozzle (or dispenser) layer by layer. In this method, using 
computer-aided design (CAD) software, the desired 3D construct model is created. By this design 
and by optimizing the printing parameters, control over the pore size, pore geometry, and spatial 
distribution of pores is possible [22].  
 
Extrusion-based 3D printing is the most common type of 3D printing in terms of various 
choices for materials, precision in printing complex structures, ease of operation, adaptability with 
many environments, and diversity of solidification approaches [23]. Using this tissue engineering 
fabrication technique also provides direct cell incorporation into the printing biomaterials [22][24]. 
Many cardiac tissue-like constructs have been printed by this method, showing successful results 
in vivo. These constructs will be discussed later in Chapter 2. 
1.4 Research Objectives 
The present study aims to develop an albumin-based bioink and on this basis, bioprint and 
characterize cell-laden patches for potential use in MI treatment. To accomplish this aim, the 
following investigations are set to be conducted.  




1) Develop and rheologically characterize the albumin-based bioink by adding minimal 
amounts of alginate for improved printability.  
2) Characterize the mechanical properties of the 3D printed albumin-based patches by 
compression testing as well as swelling and degradation behavior. 
3) Characterize the biological properties of the 3D bioprinted cell-laden albumin-based patch 
by in vitro cell viability assessment.  
1.5 Thesis Outline 
This thesis contains six chapters. In Chapter 1, MI is introduced as a life-threatening 
cardiovascular disease. Tissue engineering, as a potential treatment, and various tissue fabrication 
methods, especially extrusion-based 3D bioprinting, are discussed. Also, the research objectives 
of the present study are stated in this chapter. In Chapter 2, common printing biomaterials and 
bioinks, studied in the literature for the 3D (bio)printing of a cardiac patch, are examined followed 
by key strategies relevant to this area. Accordingly, EW is introduced as a potential beneficial 
bioink for cardiac patch 3D bioprinting. Chapter 3 presents the EW-Alg inks' preparation method, 
along with rheological assessments and 3D printing of these potential bioinks. In Chapter 4, 
compression elastic modulus, swelling ability, and degradation behavior, as mechanical properties 
of the 3D printed EW-Alg constructs, are investigated. In Chapter 5, the cell viability within the 
bioprinted HUVECs-laden cardiac patch made of EW-Alg is tested as an in vitro biological 
characterization. Chapter 6 summarizes the present study, the conclusions drawn, and the 





Chapter 2: Literature Review 
 
2.1 Introduction 
This chapter reviews the biomaterials and strategies used in 3D (bio)printing of 
cardiovascular tissues, particularly for cardiac patches. Egg white (EW) with a remarkable range 
of biomedical applications is proposed later as a potential bioink for 3D bioprinting a cardiac patch. 
Bioink is defined as the material using in tissue 3D printing when it contains cells or biological 
compartments [22]. 
2.2 Bioinks and Printing Biomaterials for Cardiac Patches 
Biocompatibility and printability are two desired features for material as a bioink in 3D 
(bio)printing. Most biomaterials used as bioink are derived from natural extracellular matrix 
sources [22]. However, synthetic materials have their own advantages, such as providing better 
mechanical support for the construct [25]. Here, natural and synthetic biomaterials used frequently 
in 3D printing of cardiovascular constructs are reviewed. 
2.3 Natural Biomaterials 
Natural cardiac bioinks include ECM-derived proteins and glycosaminoglycans (e.g. 
collagen), decellularized intact ECM or dECM (e.g. small intestine submucosa), materials derived 
from plants (e.g. cellulose), seaweed (e.g. alginate), and crustaceans (e.g. chitosan) [23]. The most 
commonly used natural materials for constructing cardiac patches via 3D (bio)printing methods 
are reviewed in this section. 
2.3.1 Decellularized extracellular matrix (dECM) 
dECM has the advantage of containing a physiological proportion of the native tissue 
components, such as the structural proteins fibronectin, collagen, laminin, glycosaminoglycans 
(GAGs) and growth factors [26]. In the case of cardiac tissue engineering, dECM can be derived 




like small intestinal submucosa (SIS) [29] and urinary bladder matrix [30]. However, preparing 
this material for tissue engineering applications needs processing, which generally takes place in 
3 steps: 
1) obtaining ECM from tissue specimens or using in vitro sheets created by cell culture;  
2) using a decellularization process; 
3) recellularizing the ECM with the desired cell type [16]. 
On the other hand, pure ECM can be challenging to use due to its soft mechanical properties 
and handling difficulties [31]. Extrusion bioprinting has attempted to overcome these problems 
through condensing ECM, using crosslinking modifications, and combining dECM with other 
biomaterials [32]. Such bioinks, combined with cells, have been proposed for cardiac tissue 
engineering in different studies [31][33]. For example, in the Bejleri et al. study, porcine cardiac 
ECM combined with gelatin methacrylate (GelMA), which provided a high degree of printability 
and proper mechanical properties for constructs, was used as the bioink of a 3D cardiac patch. This 
ECM-GelMA bioink was loaded with human cardiac progenitor cells (hCPCs), which resulted in 
the high maintainability of these cells (>75% viability), in addition to a 30-fold increase in their 
cardiogenic gene expression [34]. This ECM-GelMA-hCPCs patch also increased angiogenic 
potential (>2-fold) over the patch made of GelMA alone, by promoting endothelial cell tube 
formation. 
In another study, having dECM as bioink improved the bioactivity and cell survival of the 
construct. Endothelial induction of MSCs and enhanced functionality of hCPCs were also a result 
of the presence of a 3D printed patch composed of cardiac ECM containing vascular endothelial 
growth factor (VEGF) [35]. The developed patch also promoted remarkable vascularization and 
tissue matrix formation in vivo. The patch's 3D pattern led to enhanced cardiac functions, reduced 
cardiac hypertrophy and fibrosis, and increased migration from patch to the infarcted area. Neo-
muscle and capillary formation were also improved along with cardiac functions. This patch 
provided a cardiac niche-like microenvironment, resulting in positive effects on cardiac repair 
[35][32]. 
2.3.2 Collagen  
Collagen is one of the major components of natural ECM in adult heart tissue that promotes 




which makes it difficult to process. Therefore, collagen is usually used in combination with other 
natural or synthetic materials [36]. For example, in the Duan et al. study, collagen type I combined 
with porcine cardiac dECM in various ratios was examined to differentiate human embryonic stem 
cells (hESCs) into cardiomyocytes [26]. These hybrid hydrogels improved the contractile function 
of cardiac cells in addition to the cardiomyogenic gene expression in the applied stem cells. 
 Another way to enhance collagen’s mechanical properties to make it suitable for printing 
is by crosslinking it with different methods such as irradiation and thermal polymerization [22] 
while its biological features remain intact. Crosslinkable collagen injected into a rat model with 
ischemia-reperfusion has led to angiogenesis improvements by increasing the capillarity density 
[37]. 
Collagen might be able to be printed more easily by other methods of 3D printing. Freeform 
reversible embedding of suspended hydrogels (FRESH) is one of the 3D bioprinting techniques in 
which the material is extruded into a supportive hydrogel bath. This bath maintains the intended 
structure during the printing process and significantly improves print fidelity [38]. Collagen has 
been printed using the FRESH technique to generate human coronary vessels and trabeculated 
embryonic heart [39]. For example, a fibrinogen-collagen-Matrigel bioink containing C2C12 
myoblasts and MC3T3 fibroblasts was FRESH-printed with 99.7% post-printing cell viability. 
This study revealed that printed cells formed dense cellular networks over time in culture [26]. 
The most popular types of collagen for cardiovascular tissue engineering applications are 
collagens type I and III due to their functional role in blood vessel structure and cardiac ECM [40]. 
However, type I is the thicker fibrillary collagen with more rigidity and stability [41], which might 
make it a more suitable type for machining to build 3D bioprinted patches. 
2.3.3 Gelatin  
Gelatin is denatured collagen after heating. It is one of the commonly used materials in 3D 
printed structures with excellent printability [23]. Tijore et al. have printed gelatin hydrogels in a 
micro-channel pattern to promote myocardial differentiation of the human mesenchymal stem cell 
(hMSC) [42]. This pattern was also effective on native cardiomyocytes’ (CMs) contractile 
functionality. However, gelatin is challenging in 3D printing because of its thermosensitivity. 
Also, it melts rapidly at 37 ˚C. As a solution, combining gelatin with methacrylate can make a new 




the stability of the printed construct. It has remarkable bioactivity similar to gelatin, and enhanced 
mechanical properties which is due to its photo-crosslinked structure. GelMA has also been used 
in engineering tissue analogs ranging from the vasculature to cartilage and bone [43]. GelMA 
bioink enriched with fibronectin has shown supporting cell survival and spreading of the 
cardiomyocytes within 3D heart tissue constructs [44]. 
Gelatin has also been combined with other natural materials such as hyaluronic acid and 
alginate to optimize the patches' biological and physicochemical properties [45][46]. For example, 
in a recent study, GelMA combined with hyaluronic acid was used as the bioink for a light-based 
micro-continuous optical printing (µCOP) device to construct a human cardiac model [47]. In that 
study, researchers printed a cantilever system made of GelMA and hyaluronic acid glycidyl 
methacrylate (HAGM), which contained human embryonic stem cell-derived cardiomyocytes 
(hESC-CMs). Pairing the green fluorescent protein calmodulin/M13 peptide (GCaMP) calcium 
sensor with the printed materials helped monitor cell viability and alignment [47]. Such functional 
cardiac constructs can also help various biomedical and clinical tests such as drug discovery and 
biosafety. 
2.3.4 Fibrin  
Fibrin, an FDA-approved natural biopolymer for many medical applications, has 
competent biocompatibility and non-inflammatory properties [48]. Fibrin is obtained by mixing 
fibrinogen monomers with thrombin in saline solution. In this process, a 3D net is formed after 
polymerization, which is similar to normal clotting mechanisms in vivo. Properties of this network 
are tailorable by modifying the polymerization process [49]. 
Fibrin has a crucial role in wound healing and blood clotting. As a result, it has an extensive 
application in skin and wound repair research [50]. It is also popular in cardiovascular tissue 
engineering [51]. Fibrin improves the healing process and has a protective effect against 
myocardial reperfusion injury because it contains arginine-glycine-asparagine (RGD), promoting 
cell adhesions [52]. Besides, fibrin’s positive effect on differentiating the bone marrow stem cells 
into cardiomyocytes has been observed in studies [53]. Fibrin’s source can be the patient’s blood. 
This possibility enables fibrin to act as an autologous scaffold for tissue engineering [54]. 
Fibrin has been used in cardiac construct studies as a bioink in incorporating synthetic 




bioink was loaded with primary cardiomyocytes isolated from infant rat hearts and was printed 
inside a PCL frame to form a cardiac patch with biological and mechanical properties similar to 
the native heart [55]. This construct showed proper maturation of cells in vitro and a spontaneous 
synchronous contraction in the cell culture procedure, which mimicked physiological responses to 
applied cardiac drugs concerning beating frequency and contraction forces [55]. 
Fibrin, combined with other natural materials, has also been studied for cardiac 3D 
printing. One of the most recent studies in this area has conducted by Alonzo et al. This group 
added the fibrin to a photo-polymerizable gelatin-based bioink to fabricate cardiac cell-laden 
constructs with the human-induced pluripotent stem cell-derived cardiomyocytes (hiPSCMs), 
cardiomyocyte cell lines, and cardiac fibroblasts (CFs) [56]. They could fabricate highly porous, 
networked structures in which the integrated printed cells showed excellent viability, proliferation, 
and expression of the Troponin-I cardiac marker. Also, in their 3D bioprinted cardiac patch, the 
coupling between CMs and CFs was promoted, which is the primary step for forming normal 
physiology for the cardiac wall in vivo [56]. Generally, fibrin has shown a recurrent role in the 
bioengineering of the cardiac tissue [53]. 
2.3.5 Chitosan  
Chitosan is a cationic polysaccharide which is extracted from the chitin of mollusks, 
crustaceans, and insects [48]. It is non-toxic and biodegradable, and has antibacterial properties 
[57]. Chitosan is soluble in acidic aqueous solutions, and after neutralization, it forms a gel-like 
precipitate [58]. Due to this alteration, chitosan has been used in many tissue engineering 
applications, such as injectable in-situ forming myocardial gels [58][59][60]. Chitosan in cardiac 
tissue engineering has shown impressive results even by using chemical crosslinking without 
internal and external architectural design. Chi et al. studied a hybrid cardiac patch made of chitosan 
combined with silk fibroin-hyaluronic acid [61]. They used genipin to crosslink the hydrogel and 
then used the hydrogel directly on the MI region in a rat model. The presence of chitosan notably 
improved neovascularization, secretion of paracrine factors (such as VEGF) in the MI regions, and 
left ventricular (LV) wall thickness in a rat model. In another study, a cardiac patch comprised of 
decellularized porcine heart matrix and chitosan showed >80% viability of the cultured neonatal 




degradation rate of the patch [62]. Also, chitosan accompanying polypyrrole as a conductive 
composite for cardiac tissue engineering has been studied with gel-foaming processes [63].  
2.3.6 Alginate  
Alginate is a linear block copolymer derived from seaweed. It is a water-soluble negatively 
charged polysaccharide that becomes a gel in the presence of divalent metal ions such as Ca2+ or 
Zn2+ [22]. Alginate’s non-thrombogenic nature [64] and its ability to form a gel with a porous 
network make it a suitable material for bioprinting a tissue that can function like native 
myocardium. This porous structure allows the diffusion of nutrients and waste materials, which is 
vital for the tissue [65].  
Alginate infused with a  mixture of pro-survival factors (like stromal cell-derived factor 1 
(SDF), insulin-like growth factor 1 (IGF-1)) and angiogenic factors (like VEGF), have been 
studied in literature and exhibited positive effects on vascularization and viability of the cells in a 
cardiac patch [66]. Functionalizing the alginate-based scaffolds is also promising for the biological 
properties of this material [67]. 3D printed sodium alginate modified by the sequence of amino 
acids (RGD) and laden with human cardiac-derived cardiomyocyte progenitor cells (hCMPCs) has 
shown an excellent viability rate for the hCMPCs in vitro and promoted the differentiation of 
hCMPCs into cardiomyocyte-like cells [68]. 
Alginate has also been used in combination with both synthetic and natural materials in 
cardiac tissue engineering. Alginate modified by polyethylene glycol (PEG) and fibrinogen acted 
as an encapsulation hydrogel for printing induced pluripotent cell-derived cardiomyocytes (iPSC-
CMs) and HUVECs[69]. This cardiac tissue construct had a high orientation index imposed by 
different defined geometries and blood vessel-like shapes generated by HUVECs. After in vivo 
grafting, this patch showed cell differentiation reinforcement into the cardiomyocyte phenotype, 
improvement of cardiomyocyte alignment, and promotion of vascularization. Alginate has been 
used in several cardiovascular 3D printed constructs, such as blood vessel grafts and heart valves, 
in the literature [70][71]. 
Alginate is an affordable and manageable ink for 3D bioprinting. It can be crosslinked by 
different methods, which provides more freedom over the process. For example, printing the 




the crosslinker into the alginate solution before printing, or combining these methods, can provide 
a broad spectrum of mechanical and architectural properties. 
Typically, natural materials provide better bio-functionality and biocompatibility versus 
synthetic materials. However, due to their weak mechanical properties, poor handling, and 
relatively low printing resolution, in many studies, these materials are accompanied by synthetic 
materials [72][73]. 
2.4 Synthetic Biomaterials 
Synthetic biomaterials have tailor-made characteristics that give us a wide range of choices 
based on our target application. Among synthetic materials, polymers, metals, and alloys have high 
popularity of use in biomedical engineering [74]. The most common synthetic biomaterials in 3D 
printing technologies are polymers [22], especially in cardiovascular tissue engineering [75]. They 
often provide printability, mechanical support, shape maintenance, and chemical cues for the 
construct. 
2.4.1 Poly-ε-caprolactone (PCL)  
PCL is a popular material in different biomedical fields such as bone, cartilage, and heart 
[76]. It is a low-cost polymer with good processibility and high thermal stability, making it suitable 
for melt processing. As a result, it enables the fabrication of a variety of structures and forms [77]. 
Its widespread usage in tissue engineering as the tissue scaffold is also due to its biocompatibility 
and adjustable degradation rate [78]. However, PCL lacks bioactivity and is hydrophobic. 
Therefore, low cell affinity and a slow tissue regeneration rate are its negative points [79]. To solve 
this problem, PCL has been used in combination with more bioactive substances to improve its 
biological efficiency. PCL has been used in cardiac patches as a component of the scaffold’s blend 
to boost mechanical properties and ease the fabrication process in either electrospinning or 3D 
printing fabrication methods [80][78]. Benjamin Ho et al. fabricated a 3D extruded PCL scaffold, 
biologically reinforced by carbon nanotubes (CNTs). They used different percentages of CNT in 
their blend. The result was significant changes in mechanical properties like elastic modulus and 
hardness, thermal properties such as degradation temperature, and biological properties such as 




In another study, in a hybrid construct made of heart tissue-derived decellularized 
extracellular matrix (dECM) bioinks, printed PCL strands collaborated as the mechanical enhancer 
element. The PCL mesh provided the required stiffness needed for stem cell differentiation. 
Consequently, high-performance cellular functions such as cell survival, maturation, 
differentiation, and migration were observed in vitro and in vivo after implanting the 3D printed 
tissue construct in mice [35]. 
PCL can also be used as an attendant compartment for other biomaterials that suffer poor 
printability and processability. For instance, a composite involving PCL was studied by Yang et 
al. They used PCL to improve the mechanical properties of polyglycerol sebacate (PGS), 
specifically its mechanical fracture[81]. This combination could be printed as a highly porous 
scaffold by adding salt (NaCl) as a curing factor for high temperatures and as a porogen to make 
hierarchal pores. Due to its desirable elasticity, toughness, and biocompatibility, this patch showed 
improved cardiac function and positively impacted the progression of left ventricular (LV) 
remodeling after implantation in the rat model [81]. 
2.4.2 Polylactic-co-glycolic acid (PLGA)  
PLGA is a combination of polylactic acid (PLA) and polyglycolic acid (PGA). The ratio 
of PLA to PGA changes this polymer's biodegradation rate from a few hours to several years [82]. 
Electrospun PLGA has been used for cardiac patches combining with different natural 
compartments such as gelatin [83] or laminin derived biomolecules [84]. Besides, PLGA, as a 
guidance platform, has been used to direct the organization of the cultured cells to mimic healthy 
cardiac muscle fibers [85][86]. To do so, in one study, micro-patterned PLGA was cast in 
fluorinated ethylene propylene (FEP) plates as the mold (solvent casting method), and then human 
placental choriocarcinoma cell lines were seeded on this micro-grooved PLGA film. As a result, 
inducible arrhythmias were reduced due to this physical alignment and similar anisotropic 
electrophysiological features to the native cardiac tissue [85]. This study showed that their patch 
is considerably more refractory to premature stimuli than the random one constructed with non-
grooved PLGA film. In another study, PLGA film was used as a bottom layer for the micro-
patterned laminin lanes printed by the micro-contact printing method. Neonatal cardiomyocytes 
cultured on this patch showed rod-shaped formations with highly aligned myofibrils and bipolar 




In contrast with these merits, PLGA is not a highly recommended polymer for 3D printing 
applications due to its thermosensitivity. High temperatures may lead to structural crosslinking 
and the formation of toxic components, resulting in unpredictable behavior inside the body [20]. 
Generally, synthetic biomaterials have good strength and durability. However, their low 
biocompatibility can create complications. The most pressing concern with these materials is 
toxicity, especially in biodegradable materials, which can be degraded to potentially harmful 
byproducts in the body [74]. Therefore, natural biomaterials tend to be a more biocompatible 
choice for tissue engineering. 
2.5 Keys for 3D Printing of Cardiac Patches 
Considering tissue engineering strategies in fabricating a cardiac tissue structure can help 
achieve constructs with a higher capability to mimic the natural tissue and better integration with 
the rest of the heart. Including cells and neo-vascularization enhancer systems into the 3D printing 
biomaterial (ink) are two of the common key strategies [87][88].  
2.5.1 Cells 
After MI, the most irreversible injured part of the heart wall can be the myocardium. Since 
the numbers of cardiomyocytes are constant from a short time after birth [89], losing a large 
number of them will considerably weaken the heart’s function [90]. Besides, the destructed 
vascular system on the site is not very helpful for further healing and regeneration. Therefore, 
many cardiac patches aim to populate the infarcted region with healthy cardiovascular cells [91]. 
In the bioprinting method, cells can be combined with the printing biomaterial and implanted into 
the required region after printing. These cells can have various types and be isolated from different 





Table 2-1  Cell source in tissue engineering 
 
 
Table 2-2  Cell types and derivations for tissue engineering applications 
Cell type Advantage Disadvantage Reference 
Stem cells CSC 
(Cardiac stem 
cells) 
 Cardiac specific 
differentiation 
 Few numbers in natural 
tissue 







 Feasible isolation 
from various tissues 
 High proliferation rate 
 Multipotent 
 Extensive research 
experience 
 High paracrine 
signaling 
 Low immunogenicity 
 No arrhythmic risk 
 Difficult to extract from 
tissue 








 Vascularization ability 
 Highly metabolic 
 Secreting neuregulin 
and platelet-derived 
growth factor subunit 
β (PDGF-β) 
















Autologous  No risk for host immune 
response 
 No disease transmission 
 Cost-effective 
 Limited numbers 
 Prolonged hospitalization 
 Extra pain for the patient 
[92] 
[93] 
Syngeneic  Similar immune system 
in donor & recipient 
 Low risk of disease 
transmission 










Xenogeneic  Unlimited availability  Risk of animal-to-human disease 
transmission 
 High risk of host rejection 











 Potential for genetic 
manipulation 
 High viability rate 
 Risk of arrhythmia 









 Vascularization  
ability 
 Highly metabolic 
 Secreting neuregulin 
and PDGF-β 
 Declining performance 
with passage 











 Normal physiological 
function 
 Difficult to culture and 
maintain after certain 







One of the main challenges in tissue-engineered constructs is preparing the most 
appropriate microenvironment for cell adhesion, growth, differentiation, and other biological 
functions. After MI occurs, severe microvascular damage is seen in a significant number of 
patients [109]. Therefore, after implanting a cardiac patch, the transfer of nutrient and waste 
materials to and from the transplanted cells would be a significant concern, especially when the 
implanted construct is thick. This challenge occurs due to the long distance of cells from the 
vascular system (especially in the implant's internal parts). On the other hand, vascularization in 
the infarcted area is too slow and insufficient to solve this problem [110].  
In the healthy tissue, signaling molecules in the ECM, such as growth factors and 
cytokines, promote the biological functions perfectly, leading to tissue health and regeneration 
[111]. In constructing a tissue in the lab to mimic these processes, a transportation system is 
required to provide the natural microenvironment for proper supply, recruiting of cells, controlled 
release of ECM components, and delivery of signaling molecules [112]. 
Ideally, the mentioned transportation system needs to release its cargo in a sustained, 
controlled manner, simulating what the real healing system does in the body. This controlled 
release also is beneficial to reduce the amounts of costly signals, such as growth factors, by 
exposing them only locally within the patch. Otherwise, tiny and possibly even no growth factor 
will be received by the implant due to the growth factor being cleared by other body pathways 




Various strategies are used to provide a therapeutic sustained-release system within an 
engineered cardiac patch based on the patch fabrication method. In 3D bioprinting methods, 
bioinks can contain either vascularization enhancer cells (beneficial in the long term) such as 
HUVECs, or growth factor cargoes (profitable in a shorter time) such as VEGF. In the first case, 
the construct's loaded cells can gradually proliferate and secrete ECM with valuable signaling 
components. Also, vascular cells or stem cells can initiate the formation of vascular networks in 
the implant site and into the immediate neighborhood to gather body fluids for more integrity. In 
the second case, patches can be functionalized by an operative growth factor delivery system with 
controlled released behavior that can gradually deliver an optimal amount of nutrients and drugs 
to the site’s cells, starting right after implantation. 
Nanoparticulate drug delivery systems in which commonly polymeric nanoparticles can be 
loaded with angiogenetic growth factors such as PDGF, VEGF, and basic fibroblast growth factor 
(bFGF) [113] are one of the engineering solutions for functionalizing the patches. However, 
drawbacks such as the unknown fate of nanoparticles, accumulation in other organs [114], risk of 
crossing the blood-brain barrier [115], and their degradation time and destructive side products 
[116][117] lead to hesitations in applying them beyond research studies. 
Another delivery system for biological factors in tissue engineering scaffolds uses 
materials that can act as reservoirs and release their attracted growth factors/drugs when the patch's 
scaffold is degrading. EW is one of these materials that, due to having helical protein structures of 
albumin (Figure 2-1)[118] has many binding sites and can absorb various drugs. Hence, albumin-





2.6 Physiological Properties and Applications of Egg White in Biomedical 
Engineering 
Among different natural biomaterials, albumin is a highly bioactive, available, and easy to 
handle material with low production costs compared to other proteins such as collagen or 
fibronectin [120]. Studies show the albumin biological and mechanical properties as a practical 
biocompatible biomaterial in tissue engineering and other biomedical research [121][122][123].   
Albumin can be derived from a variety of sources. As an autogenic source, a person’s blood 
plasma is enriched with albumin (half of the total protein in the plasma) [122]. However, in a 
clinical setting, taking the albumin from the patient’s blood has a low yield and requires a 
significant amount of blood, making the procedure invasive [120]. Moreover, appropriate diet and 
exercise for this harvesting procedure are required, along with accurate monitoring the hemoglobin 
immunoglobulin, erythrocyte volume, and total serum protein level [124][122].  
An off-the-shelf, low-cost alternative source of albumin is egg white (EW). EW's main 
proteins are ovalbumin, conalbumin, and lysozyme, which have essential biological roles, 
Figure 2-1  Three-dimensional structure of serum albumin 




including embryo protection and development [125]. Biodegradation of these proteins to their 
building blocks (amino acids) can provide the required nutrients for cells in their environment 
[121]. Therefore, chicken EW has been suggested as an available alternative model for 3D cell 
culture studies [125]. For example, in Guo et al.’s 2017 research, aggregation of ovarian carcinoma 
cells was observed on the EW constructs fabricated through a cryogelation process. These 
constructs could provide a suitable mechanical and biological environment for these cells' 
proliferation and progression [126]. 
From the biological point of view, albumin as a coating layer in cell culture has shown that 
it can provide an interface between scaffold and cells and improve the interaction as a mediator.  
Albumin has shown even better efficiency than collagen and fibronectin in enhancing the cell-
material attachment [127]. This material can be degraded by the surrounding cells in the body’s 
environment, and its monomers (amino acids) are biocompatible [127].  
Albumin has excellent compatibility with cells and is a good support for the differentiation 
of stem cells in bone and nerve tissue engineering. Li et al., in 2014, fabricated 3D sponges from 
enzymatic polymerized albumin as the scaffold for bone tissue regeneration. They cultured human 
MSCs and showed considerable cell viability and activity even after three days. Furthermore, in 
the presence of an osteogenic culture medium, seeded MSCs on these sponges showed remarkable 
osteogenic differentiation [122]. In another study, serum albumin-based fibrous scaffolds showed 
enhancement of the attachment, proliferation, and neuronal differentiation of hiPSC-derived neural 
stem cells (NSCs) [128].  
Albumin also has suitable mechanical properties such as good elasticity, structural and 
biochemical properties [122]. Compared to PLLA/ PLGA and PCL nanofibers scaffolds, albumin 
nanofibrous structures have shown a more similar mechanical behavior to the elastin fibers in 
connective tissue ECM and had higher flexibility than those scaffolds made of PLLA/ PLGA and 
PCL [129]. In Nseir, et al.’s 2013 study, albumin-based scaffolds also showed a non-toxic nature 
and supported adhesion and the spreading of fibroblasts, muscle cells, and endothelial cells (ECs) 
in vitro. The fabricated albumin tubular electrospun structures designed to mimic blood vessels 
could successfully guide the formation of blood vessel-like bi-layer structures made of fibroblasts 
and ECs. 
Generally, albumin, in addition to supporting cell growth and differentiation, has a 




mimic the tissue’s natural microenvironment [119]. Accordingly, albumin is also beneficial in 
cardiac tissue engineering as tissue’s scaffold or structural component. In a recent study, 
Amdursky et al. showed that bovine serum albumin hydrogel has the potential to mimic the rigidity 
and deformability of the native cardiac tissue [128]. Their albumin-based hydrogel could support 
the formation of several layers of cardiomyocytes and significantly promoted the maintenance of 
the gene expression pattern similar to the native heart tissue. As an underlying substrate, this 
hydrogel showed the ability to induce macroscopic cardiac-like contractions, which could stably 
function for at least 14 days. The formation of mm-long vascular-like structures resulted from 
using this albumin-based hydrogel in their study [130]. In another study, electrospun albumin 
scaffolds showed a similar elastic modulus to the natural cardiac tissue ECM rather than fibers 
made of PCL that is a commonly used synthetic polymer in fabricating engineered cardiac 3D 
constructs [121].  
Albumin bioengineering applications in the cardiovascular field are not restricted to tissue 
scaffolds. Sealants are another application for albumin in biomedical research; for example, 
albumin-based bioGlue acts as a hemostatic adjunct for cardiac and vascular surgeries [131]. 
Albumin-based sealant has been tested in pigs and has shown excellent expansion and minimal 
inflammation within three months [132].  
Another advantage of albumin that has been substantially emphasized in the literature is its 
cargo delivery potential because of the albumin protein structure, which has a high affinity to many 
drugs (Figure 2-1) [118][133][134][119]. This feature makes albumin a decent choice to absorb 
the cytokines/growth factors from the environment and then release them slowly during the tissue 
remodeling [63]. In 2015, Jalili et al. fabricated EW albumin sponges for wound-healing 
applications [120]. Their optimized sponge led to higher angiogenesis than the collagen sponge, 
which is a commonly used biomaterial in skin repair and tissue engineering [135]. This 
enhancement was explained as a result of significantly higher adsorption of the proangiogenic 
vascular endothelial growth factor (VEGF) by their EW scaffolds [120].  
Albumin has also been investigated for exhibiting antibacterial behavior. Arzumanyan et 
al. researched three different types of albumin (bovine serum, human albumin, and ovalbumin) 
effects on Candida albicans, Cryptococcus neoformans, E. coli, and Staphylococcus aureus cells 
[136]. All types of their studied albumins showed antimicrobial activity, which leads to a 




Also, EW as an embryogenesis environment, has various proteins and enzymes (e.g. lysozyme, 
which disrupts the bacterial walls) helping to overcome a wide range of microbial microorganisms 
to protect the embryo [137]. 
All these properties mentioned for the albumin indicate the biomedical potential of this 
biological material in diverse areas. EW, as an albumin-enriched, biocompatible, and mechanically 
strong material, meets the requirements to contribute to tissue patch construction. In the meantime, 
it can save the expenses of patch sterilization procedures owing to its antibacterial features. Based 
on these findings, albumin might be a suitable choice as a natural bioink for 3D bioprinting of a 
cardiac patch. 
2.7 Conclusions 
This chapter presented a literature review of the biomaterials used in 3D bioprinting and 
identified the differences and gaps between natural and synthetic materials, which should be noted 
in creating tissue-like constructs with appropriate mechanical/biological properties. Egg white is 
a natural, abundant material with a high dose of biological cues and tailorable mechanical 
properties. This material has shown successful results in cell growth and proliferation in literature 
along with well-known drug delivery features. Therefore, EW can be a wise choice to be used as 









For this thesis work, the first step in fabricating the cardiac patch was preparing and 
characterizing the albumin-based (bio)ink. Due to using an extrusion-based 3D bioplotter, the EW 
needed to have a certain extrudability. This material also needed to become solid after printing to 
form a stable 3D printed construct, which could mechanically and biologically be characterized. 
Sodium alginate, a natural biomaterial with a vast application in 3D bioprinting (discussed in 
Chapter 2),  and possessing an ionic crosslinking procedure, could properly do this job. 
In this step of the study, the aim was to gain favorable properties in 3D printing the 
construct by adding the minimal amount of alginate into the EW to achieve the printability (fine 
extrusion). Then, rheological characterizations were performed, and suitable blends underwent 3D 
printing. 
3.2 Materials and Methods 
3.2.1 Ink Preparation 
EW-Alg blends were prepared by adding sodium alginate powder (Medium viscosity, 
Sigma Aldrich) into pasteurized egg white (purchased from a local grocery store). Five different 
concentrations of sodium alginate powder in EW were prepared by dissolving 1.0, 1.5, 2.0, 2.5, 
and 3.0% (w/v) alginate powder in EW fluid and stirring by a magnetic stirrer. After reaching 
homogeneity, solutions were neutralized to pH∽7 by 0.5 M hydrochloric acid (HCl, 36.5-38.0%, 
Sigma Aldrich). Later, they were centrifuged to reduce the bubbles formed due to mixing, to obtain 




 3.2.2 Rheological Characterizations 
The flow behavior and viscoelastic properties of the prepared EW-Alg blend were studied 
using a rheological test on each concentration of the EW-Alg blend at two different temperatures, 
i.e. 25 °C (room temperature) and 37 °C (body temperature).  
Rheological measurements were performed using a rheometer (RVDV-III Ultra 
Brookfield, USA) with a cone and plate geometry of 40 mm diameter and 2° angle. For every 
single test, 2 ml of the considered ink was put inside the instrument’s plate and heated up to the 
desired temperature (25 or 37 °C). After reaching the steady-state temperature, rotation started 
with the speed increments of 5.00, 1.00, 0.50, and 0.10 rpm for the blends of EW-1.5%Alg, EW-
2.0%Alg, EW-2.5%Alg, and EW-3.0%Alg, respectively. Shear rate, shear stress, viscosity, and 
torque were sampled using Brookfield software. Shear stress versus shear rate, and torque versus 
viscosity graphs were then plotted based on the collected data for each ink. For each concentration, 
at least five tests were run per each temperature point. 
3.2.3 3D Printing of Patches 
3D patches were fabricated at room temperature by a pneumatically controlled extrusion-
based 3D-bioplotter (EnvisionTEC GmbH) (Figure 3-2). The 3D structure of samples was 




designed using Magics EnvisionTEC (V13, Materialise), Bioplotter RP (V2.9, EnvisionTEC 
GmbH), and Visual Machine BP (V2.2; EnvisionTEC GmbH) software. Patches were printed in 
10 layers with a surface area of 12 mm ×12 mm and a height of 8 mm. The inner strands structure 
was designed as a 1.5 mm distance between strands with a 90° hatch pattern. Plastic dispense tips 
of gauge 25 (EFD Nordson, USA) were used for manufacturing all the groups. EW-Alg solutions 
were loaded into the 3D bio-plotter dispenser. A speed of 9, 10 and 11 mm/s, and a pressure of 
0.3, 0.5 and 0.8 bar was used to print EW-2.0%Alg, EW-2.5%Alg and EW-3.0%Alg constructs, 
respectively. Strands were dispensed into 6-well plates containing a crosslinker bath of 25mM 
CaCl2 and 0.25% (w/v) polyethyleneimine PEI. Printing plates had been coated with 0.1% (w/v) 
PEI one day before. Patches were kept overnight in 500 mM CaCl2. Then samples were washed 
five times with distilled water, followed by 70% ethanol, and were then held in PBS overnight to 
be balanced with a biofidelic fluid before conducting the mechanical characterizations (Figure 3-
2). 




3.3 Results and Discussions 
3.3.1 Rheological Studies 
Equation 3-1 shows viscosity as a function of shear stress and shear rate for each data point 
where the τ (Pa) is shear stress, γ (s-1) is the shear rate, and μ demonstrates the viscosity (Pa•s). 
μ = τ/γ          (3-1) 
Shear stress vs. shear rate and viscosity vs. torque graphs of all samples have been 
summarized in Figures 3-3 and 3-4. These results showed notable differences among the groups 
of concentrations.  In short, the ink gained a thicker texture and higher viscosity, per 0.5% added 
alginate. A thicker fluid required more torque to shear off per constant amount of shear rate, and 
the higher torque indicated a higher amount of shear stress applied. 
 
Figure 3-3  Rheological curves of shear stress versus shear rate per percentage of Alg in EW for all prepared 





In addition to the Alg concentration in the blend, temperature also influenced the EW-Alg 
fluid thickness. All inks at 25 ˚C possessed a thicker texture compared to their 37 ˚C states; this 
showed an inverse correlation between the viscosity and temperature. However, the impact of 
temperature change (from 25 ˚C to 37 ˚C) was not as significant as alginate concentration 
increments in the inks. 
All the blends of EW-Alg showed a non-Newtonian shear-thinning behavior in which when 
the viscosity decreased the shear strain and torque increased. The best-matched curve following 
the trend of shear stress vs. shear rate curves for all samples was the power function, as labeled on 
each curve.  
 
It is worth pointing out that the blend of EW-1.0%Alg was not thick enough to apply an 
adequate torque in the measurable range of the rheometer machine to perform the test (% torque 
<10 for the RVDV-III Ultra Brookfield rheometer, spring torque = 0.7187 mN.m), and an under-
range error occurred.  
Figure 3-4  Rheological curves of viscosity versus torque for all prepared EW-Alg blends per percentage of 




Also, since the shear rate measurements for the EW-1.5%Alg ink exceeded 100 s-1, the 
shear rate axis was cut in Figure 3-3 for values more than 100 s-1 to illustrate all the charts in one 
graph. Full-range charts are presented in Appendix I. 
According to the rheological studies, higher pressures are needed for the extrusion of 
thicker blends. The higher printing pressure means that biological cells loaded into the bioink may 
bear higher shear stress levels. Depending on the cell type, high shear stress can be harmful in 
different ways, such as hurting the cell membrane and/or changing the cell behavior and fate in 
the long term [138].  
3.3.2 Bioprinting Patches 
Prepared EW-Alg blends were all tested for their 3D printability.  The observed result was 
that 3D printing was successful on the EW-2.0%Alg, EW-2.5%Alg, and EW-3.0%Alg inks. In 
these constructs, the shape of 3D printed strands and the hatch angle (90˚) remained accurate after 
crosslinking and maintained good uniformity (Figure 3-5). For the 3D printing process, as expected 
from the rheological studies and among the three successful concentrations, EW-2.0%Alg was the 
ink that used higher speeds and lower pressures to fabricate the same architectural design as in 
EW-3.0%Alg. 
In comparison, the EW-1.0%Alg, and EW-1.5%Alg blends did not exhibit fidelious 
printability. This lack of feasibility was due to the ink being too watery, lacking extrudability, 
having too low viscosity, and being unstable during crosslinking. These led to fabrication 
challenges, such as unattached printed layers, irregular strands, and ink sticking to the dispenser 





Figure 3-5  3D printed EW-Alg patches from Side view (a), Top view (b), 
and c) a microscopic view of strands interval with uniform strands 
Figure 3-6  Difficulties during the 3D printing procedure of EW-1.5%Alg blend. Unattached 
strands leading to clogging the needle (a), instability of the printed structure in the crosslinker 





In fabricating a tissue construct by 3D bioprinting methods, characterization of flow 
behavior and rheological properties of the printing biomaterial can provide helpful information for 
predicting the material’s parameters during 3D (bio)printing.  
In this chapter, EW-Alg blends (inks) were prepared in different ratios of added Alg 
concentrations. Rheological studies that illustrated the viscosity behavior were performed in two 
constant temperatures (25 ̊ C & 37 ̊ C) based on the Alg concentration within the ink. These studies 
showed a non-Newtonian shear-thinning behavior for all inks, in both temperatures as well as 
higher shear stresses when running the thicker inks. 
The 3D printing procedure was successful only on three concentrations: EW-2.0%Alg, 
EW-2.5%Alg, and EW-3.0%Alg blends. As the lowest viscosity needed the lowest shear stress 
during extrusion, EW-1.5%Alg could have been the best choice among the rheologically 
characterized inks. However, it did not show good fidelity as a hydrogel construct while and after 
3D printing. Therefore, the EW-2.0%Alg blend, as the least viscose ink among remaining inks that 
also presented excellent handling properties with high fidelity in printing, seems to be the best ink 









After 3D printing the EW-based patches, the mechanical properties of these constructs 
were investigated to determine (1) if these patches are mechanically reliable to act as successful 
tissue scaffolds and (2) if changing the concentration of alginate with the step of 0.5% is 
significantly impacting the mechanical properties of the 3D printed constructs. Thus, the elastic 
modulus, swelling, and biodegradability of the 3D printed patches were studied and presented in 
this chapter. 
4.2 Materials and Methods 
4.2.1 Mechanical Strength Characterization 
One of the principle tests to study objects' mechanical strength is conducting a compression 
test to predict the object’s response under compressive loading and its ability to tolerate the applied 
load without failure or plastic deformation. Herein, this test was performed for investigating the 
elastic moduli of the 3D printed patches. To do so, unconfined compression at room temperature 
at a rate of 0.01 mm/s, with a preload of 1 N, was applied on each patch using a biodynamic 
mechanical testing machine (BioDynamic 5100 Bose). Compressive elastic modulus (EC), which 
is the ratio of the applied stress difference to the corresponding strain difference was calculated 
using the Equations 4-1, 4-2, and 4-3. 
 
σ = F/A         (4-1) 
ε = ΔL/L0; ΔL = L-L0        (4-2) 
E = σ/ ε         (4-3) 
 
Where σ is the compressive stress, F ˗ the force, A ˗ the cross-sectional area, ΔL ˗ the change in 




More than four samples of each group were tested; and the average values of tests were 
used to plot the stress versus strain curves. 
4.2.2 Swelling and Degradation Characterizations 
As myocardial infarction healing is a kind of wound-healing procedure, providing an 
environment with the ability to absorb water and water-soluble biological cues can keep the wound 
moisturized and promote faster healing [139]. In this study, the ability of constructs to absorb fluid 
from the aqueous environment was characterized by a swelling test. In this test, each patch’s 
freeze-dried weight (W0) was measured. Then, patches were fully immersed in phosphate-buffered 
saline (PBS) at a 37 °C and 5% CO2 incubator. After 24 h, swollen patches were taken out of the 
solution. A filter paper removed the excess solution. Then each wet sample was weighed and this 
weight was recorded as the wet weight (Ww). The swelling ratio of each sample was calculated 
according to Equation 4-4: 
 
S = [(Ww – W0)/ W0] × 100%       (4-4) 
 
On the other hand, to analyze the 3D printed patches' biodegradation behavior in a body-
like environment, lyophilized 3D printed patches were put inside the PBS for 28 days. PBS was 
changed twice a week to keep the solution fresh with constant ion concentration.  
4.2.3 Statistical Analysis 
The statistical significance of the results was calculated using a one-way analysis of 
variance (ANOVA).  Pairwise comparisons were performed using the T-test found in Excel. P-
values <0.05 were considered statistically significant. 
4.3 Results and Discussion 
4.3.1 Mechanical Strength  
The elastic modulus of each stress/strain curve was obtained by calculating the slope of the 
linear region of the curve. Figure 4-1 illustrates the results. By increasing the alginate 




structures within the construct due to having a more ionically condensed blend in higher 
concentrations. i.e. due to having more alginate in the constructs, the ratio of Na+ exchanged with 
Ca2+ became greater, and more crosslinking formed stiffer constructs. ANOVA analysis showed a 
p-value of <0.05 between all groups. Pairwise T-test comparisons showed a significant difference 
in elastic moduli between EW-2.0%Alg and EW-3.0%Alg samples. In contrast, the alteration is 
not very notable per each 0.5 % addition of alginate. 
Based on the literature, the human cadaver limb compressive elastic modulus is in the range 
of ∽20-38 kPa for males and ∽10-32 kPa for females [140]. Furthermore, the porcine cadaver 
heart (LV part) has shown compressive elastic moduli in the range of ∽2-8.5 kPa and a range of 
∽1.5-6 kPa for its decellularized form (heart ECM) [141]. 
On the other hand, many commercial silicon-based materials used in soft tissue modeling 
have compressive elastic modulus values close to those of the fabricated EW-Alg patches. Dragon 
Skin (Smooth-On, Easton, PA) with 20-850 kPa and Semicosil 921 (Wacker Solutions, Adrian, 
MI) with 25 kPa  (Appendix II) [142] are some of these products. 
Therefore, as the EW-Alg patches have similar compressive elastic moduli to the 
mentioned cases, they may have a promising potential to act as a platform in mimicking the soft 
tissues such as muscles. 




4.3.2 Swelling and Degradation Behaviors 
All three groups of patches showed swelling ratios of more than 1800%, representing 
excellent water uptake ability. EW-2.0%Alg patches exhibited the highest values (Figure 4-2). 
This water storage is a positive feature in tissue engineering since water-soluble growth factors, 
minerals, and other biological cues can be entrapped within the 3D patch pores and exposed to the 
implanted cells. The conducted swelling test also indicated that even if these EW-Alg 3D printed 
constructs are simply used as spongy scaffolds, they can uptake large amounts of body fluid and 
ions and transform the dry sponge into the wet hydrogel again. 
 
In the biodegradation test, no weight changes were observed in the samples on days 7, 14, 
and 21. However, structural destruction of patches was observable and samples were softer in 
texture. These changes were more tangible after day 21. On day 28, surface strands were being 
dissociated, and constructs were fragile to touch (Figure 4-3). The day 28 time-point was chosen 
for observation as it is an average time for the ending stage of cell proliferation, overlapping with 
the beginning of tissue remodeling. This time is reported as 10-14 days for cutaneous wound 
healing, 14-35 days for bone remodeling [143], and 14-28 days for ligament repair [144].  
Figure 4-2  Swelling behavior of 3D printed EW-Alg patches after 24h 





In this test, measuring the degradation rate by weight seemed to need a harsher environment 
like a collagenase enzyme to have measurable weight changes. However, PBS is a frequently used 
buffer in biological studies, mimicking the human body's osmolality and ion concentrations [145]. 
It should be pointed out that the 3D patches tested in this chapter were all cell-free constructs. 
Presenting cells can accelerate the degradation rate as the cells will digest the patch during their 
proliferation. The other factor is the lack of fluid flow (such as blood flow). The performed 
degradation test was conducted statically. However, it is expected to have a faster degrading 
procedure in the presence of body fluids’ circulation [146]. In addition, tissue movements (such as 
heartbeat) might also speed up this degradation rate. 
4.4 Conclusions 
3D printed patches from the three optimized blends of EW-Alg solutions (2.0, 2.5, and 
3.0% alginate in EW) were tested mechanically to determine the best blend to act as a potential 
bioink (cell-laden ink) in biological studies presented in the next chapter. For this purpose, the 
elastic modulus, swelling, and degradation behavior of all three groups of 3D printed EW-Alg 
blends were characterized. As the results showed, all three 3D printed constructs of EW-2.0%Alg, 
EW-2.5%Alg, and EW-3.0%Alg had mechanical strength similar to cadaver muscle tissues and 
silicon-based materials used in soft tissue modeling. Particularly, the EW-2.0%Alg patch had the 
closest elastic modulus to the porcine heart's modulus and its decellularized ECM, measured in 
literature. 
Swelling measurements demonstrated these 3D printed EW-Alg patches' ability to uptake 
ionic fluids with a slightly higher amount of swelling for the EW-2.0%Alg patch. All of the 
constructs showed signs of biodegradation within a month, indicating the durability of this patch. 
Figure 4-3  Degraded patches made of the blends (a) EW-2.0%Alg, (b) EW-2.5%Alg, 




Based on this chapter's results, EW-2.0%Alg ink is considered the optimum solution for 









Based on the preceding chapters' results and findings, the EW-2.0%Alg blend was selected 
as the most suitable (optimum) candidate for cell loading, particularly with the following 
considerations.  
1) It contains the highest amount of egg white (albumin protein) as the leading material with 
desirable biological cues 
2) It has the lowest viscosity, requiring less extruding pressure and shear stress to be applied 
during the 3D bioprinting procedure. 
3) It has the closest elastic modulus to the porcine heart tissue. 
4) It shows a strong ability to uptake aqueous fluid and then biodegrades in a biological 
environment.  
In this chapter, EW-2.0%Alg was loaded with HUVECs, which was then bioprinted into 
cardiac patches. These cell-laden patches were characterized in terms of biocompatibility to see if 
the performed procedures of patch fabrication (including the biomaterial blending and 3D 
bioprinting) influenced the cell viability and proliferation within the patches. HUVECs, a type of 
vascular stem cell, are commonly used in cardiac tissue engineering [147][69]. Therefore, the 
survival and proliferation of HUVECs can be interpreted as a positive sign of this potential cardiac 
patch in vitro. 
5.1.1 Biocompatibility 
There are various definitions for the biocompatibility criteria of a material. However, the 
common point in these definitions is that a biocompatible material can perform its specific 
application with an appropriate host response [148]. The minimum requirement in this regard is to 
be non-toxic and/or not to develop toxicity. Biocompatibility can be a grayscale criterion and 
depends on the application. Enhancing cell proliferation and tissue regeneration can be considered 




cancer therapy. Biocompatibility also depends on the duration that the material is supposed to be 
used [149]. One material can be biocompatible for a specific tissue for a short time but harmful in 
the same tissue for long-term applications. 
5.1.2 In Vitro Cell Study 
Lab engineered cardiac tissues need to provide conditions that can simulate the natural 
heart tissue ECM. In this respect, a protein/polysaccharide-based 3D porous environment 
accompanied by vascular cells might help mimic the initial stages of forming a vascularized 
cardiac tissue. Therefore, the fabricated EW-Alg patch, having a high amount of amino acids and 
bioactive sites, was expected to show prosperous cell viability in vitro.  
5.2 Materials and Methods 
5.2.1 Cell Culture  
HUVECs (ATCC, Rockville, MD, USA) were cultured in a complete culture medium 
consisting of Dulbecco’s Modified Eagle Medium (L-glucose DMEM, Gibco), 10% 
hypoxanthine-aminopterin-thymidine (HAT, Gibco), 10% fetal bovine serum (FBS, Gibco), and 
1% penicillin-streptomycin antibiotics (PS, Sigma-Aldrich, Canada) [150]. After the cells covered 
the culture flask (80% confluency), cell passage/subculture was performed. Cells were detached 
using 0.025% trypsin for 2 minutes in the incubator at 37 °C with 5% CO2. Trypsin then was 
neutralized by the complete culture medium (containing FBS). The dissociated cell suspension 
was centrifuged at 1200 rpm at 4 °C for 5 minutes. The supernatant was removed and the pellet 
was cultured again. Passage IV cells (with normal activity and confluency) were used for 3D 
bioprinting.  
5.2.2 Cell-Laden Bioink Preparation and 3D Bioprinting 
To prepare a bioink, pasteurized EW was mixed with sterilized Alg powder, which 
formerly was sterilized under a UV lamp (250 nm wavelength) for 2 hours. EW-2.0%Alg blend 
was prepared and neutralized by filtered HCL to pH∽7. The cultured HUVECs suspension was 
added to the blend and was gently stirred to achieve a homogenous bioink. All the printing plates 




laden bioink was then loaded into the bioplotter dispenser and was 3D bioprinted in the autoclaved 
CaCl2 bath of 25 mM plus 0.25% PEI. Shortly after printing, the bath was changed with 500 mM 
CaCl2 for 10 minutes and then was changed with the complete culture medium three times. For 
this biological assay, 3D patches were bioprinted in 3 layers.  
5.2.3 Cell viability assessment 
A live/dead assay was performed to observe the cell viability and proliferation of the 
bioprinted HUVECs within the bioink at different times. This assay is a two-colored staining using 
fluorescence microscopy. Calcein-AM dye was used for green fluorescent staining of the live cells, 
indicating the intracellular esterase activity. Simultaneously, Propidium Iodide (PI) was used to 
red fluorescent stain the dead cells addressing disintegration in their plasma membrane. 
Calcein-AM and PI dyes were dissolved in PBS with the final concentration of 1 and 0.5 
μL/mL for staining live and dead cells, respectively. For each time point, culture medium was 
removed from the plates and the dye mixture was added into the 3D bioprinted patches and kept 
for 30 minutes in the incubator (37 °C, 5% CO2). Three samples per each time point were imaged 
using a fluorescence microscope. 
The percentage of cell viability was calculated using Equation 5-1, after counting by Image 
J software. 
 






5.3 Results and Discussion 
This patch had the potential to be 3D bioprinted successfully in 12 layers with high fidelity 
(Figure 5-2).  
Figure 5-1  Cell viability and proliferation of 3D bioprinted HUVECs within the EW-2.0%Alg 
bioink by live/dead assay 1, 4, and 7 days after printing. Note (a) fluorescent microscopy, and (b) 





The live/dead assay was conducted on days 1, 4, and 7, after printing. Results in Figure 5-
1 show that HUVECs maintained their viability within the 3D printed patch and the ratio of dead 
to living cells remained very low (<10%) at all the time points after bioprinting. It also showed a 
high rate of HUVECs proliferation which led to a confluent patch on day 7. The formation of 
capillary-like structures, visible on day 7 (Figure 5-3) is another affirmative sign for 
neovascularization and microvessel formation within this cardiac patch.  
 
Figure 5-2  3D bioprinted HUVECs-laden potential cardiac patch with 12 layers in complete 
DMEM from different views 
Figure 5-3  Vascular-like HUVECS aggregations (inside dashed 
areas) within the EW-2.0%Alg bioprinted patch, showing the initial 





In this chapter, the optimized EW-Alg blend was utilized as a cell-laden bioink to 3D 
bioprint the cellular cardiac patches. The 3D bioprinted cardiac patch biocompatibility was tested 
by investigating the behavior of loaded HUVECs within the 3D construct over seven days.  Cell 
viability was analyzed at 3 time-points: days 1, 4, and 7 post bioprinting. High cell viability (more 
than 90%) and proliferation were observed. Capillary-like cell aggregations were also evident in 
the fluorescent microscopy that shows neovascularization initiation within the patches. Therefore, 
with exhibited positive in vitro results, this patch might have good potentials to be characterized 





Chapter 6: Summary, Conclusions, and Future Prospects 
 
6.1 Summary and Conclusions 
In the present study, EW-Alg was developed as a novel bioink for 3D cardiac patch 
bioprinting; and its potential was investigated in terms of 1) rheologically studying various 
concentrations of the Alg in EW, and 3D printing the EW-Alg blends, 2) characterizing the 
mechanical properties of the cell-free 3D patches, and 3) analyzing the biological activity of 
HUVECs-laden patches made of the best EW-Alg blend. 
Four blends of EW-Alg were prepared with varying concentrations of Alg dissolved in EW 
and then tested in terms of their rheological behavior at two temperatures of 25 and 37 °C, 
respectively. EW-Alg showed a shear-thinning behavior in which the viscosity was decreasing 
under increasing shear strain. Raising the Alg concentration in the blend led to higher shear stresses 
since the fluid became more viscose. Also, temperature showed a reverse correlation with viscosity 
and the applied shear stress. Based on this experiment, EW-Alg blends with lower amounts of Alg 
were recommended to use as a bioink, since they would need lower extrusion printing pressure 
and would experience lower levels of shear stress during the printing procedure.  
The EW-Alg blends with varying ratios of EW to Alg were printed to observe if similar 
3D constructs were formed visually. The results illustrated that the EW-1.5%Alg blend did not 
show good fidelity in the 3D printing procedure as it was very watery, while the other three blends 
successfully formed  3D structures. 
The compressive elastic moduli of 3D printed patches were considered a parameter to 
mimic heart-muscle mechanical properties under physiological compressive forces. Increasing Alg 
concentrations led to higher elastic moduli since the patches were chemically more crosslinked. 
All the EW-Alg patches groups showed the elastic moduli (∽20-27 kPa) close to that of the human 
cadaver limb muscles (∽10-38 kPa) and many commercial silicone biomaterials with soft tissue 
modeling applications (Appendix II). Among all groups, the EW-2.0%Alg patch had the lowest 
compression elastic modulus, which was the closest to the measured value for porcine heart and 




The swelling capacity and degradation behavior of each group of patches were studied in 
PBS. The 24 h swelling test showed all patches' capacity to absorb ionic fluid was more than 
1800%, with a slight difference among groups. This ability shows the spongy potential of EW-Alg 
patches in absorbing the body fluid from the environment and providing the implanted cells with 
necessary growth factors and other biological cues.  
Degradation of constructs was visible after 28 days in the form of strand disintegration in 
the meshed 3D EW-Alg patches. This phenomenon shows the biodegradability of the patches, 
which is a desired feature.  One wants this to occur in the body as the tissue is regenerating. 
Besides, it indicates that the meshed design can still present decent durability until the tissue 
regenerates. Many natural biomaterials, such as gelatin and collagen, lack this durability and 
degrade within a short time before the tissue remodeling is completed. 
After the performed characterizations, the EW-2.0%Alg was chosen as the optimum bioink 
for the 3D bioprinting of the cell-laden cardiac patch. A live/dead cell viability assay was 
performed to show the viability and proliferation of the 3D bioprinted HUVECs. Cell viability of 
>90% was observed at every time point after bioprinting. 
To conclude, in this study, the EW combined with a minimal amount of Alg in the range 
of 2.0-3.0% (w/v) were synthesized and then successfully printed to form 3D patches; these 
patches showed mechanical properties similar to the natural ECM, as confirmed by the 
compressive testing. The EW-2.0%Alg was considered the most appropriate for use as a bioink, 
and further tested in terms of biocompatibility through HUVECs, illustrating their high cell 
viability and proliferation within the 3D bioprinted patches.  
6.2 Recommendations for future work 
Based on the literature and performed work in this thesis, the following recommendations 
are proposed for further steps:  
1- This study has been performed thoroughly in an in vitro phase. Considering these results, 
the cell-laden 3D bioprinted patch has the potential to be implanted in an animal's cardiac infarcted 
area for in vivo studies.  
2- In this work, Alg was used to enhance the eggwhite's extrudability for 3D bioprinting. 
Other natural biomaterials might also be useful in this case. However, various factors should be 




processability can be some of these concerns. As part of this thesis work, some pilot studies 
performed in this regard are presented in Appendix III. 
3- The EW-Alg solution in this study was characterized in its intact blend form without 
any other chemical or biological modification. However, considering the EW as a drug carrier with 
a high affinity to a wide range of drugs, targeted manipulations might be feasible. For example, 
combining other biological components into the bioink, such as growth factors or other bioactive 
molecules, can improve vascularization or direct the stem cells' differentiation.   
4- EW-Alg blends can also be heated and form other types of porous structures, which can 
also be extruded and 3D printed. However, in this case, as they turn into a solid gelly form, 
incorporating the cells for 3D cell-laden bioprinting becomes almost impossible. The alternative 
approach would be culturing the cells on a solid 3D printed scaffold. Heating the scaffold in 
addition to creating a microporous structure within each strand, could also be a decent method of 
sterilization. Appendix IV shows some effort in this area that was performed as part of this thesis 
work. 
5- In the biological assay portion of this thesis, cell proliferation of the HUVECs was 
considered the first step in successful tissue regeneration. Albeit, there should be a time that these 
cells stop/slow down their division after complete tissue formation. This inhibition can be set up 
by engineering the cell DNA. Moreover, to make a cardiac tissue more similar to the natural one, 
the type and ratio of somatic cells to stem cells can also impact the regeneration result.  
6- As the architectural design, ratio of EW to Alg, preparation, and crosslinking agent can 
all change the mechanical properties of the 3D printed constructs, the EW-Alg blend might have 
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a) Efforts to 3D print constructs made of EW 40%w + Sugar (glucose) 60%w solution 
(meringue). 
 






Heated form of EW-2.0%Alg after autoclaving. Porous bulk (left), extruded form within the CaCl2 
25mM bath (right). 
 
